Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp. is a biopharmaceutical company focused on developing therapeutics for central nervous system disorders, immunology, infectious diseases, and rare diseases, aiming to address significant unmet medical needs. Tonix Pharmaceuticals Holding Corp. develops innovative therapeutics targeting various medical conditions.

The company, headquartered in New York, US, was founded by Avi CEng. It secured USD 30. 00 mn in PIPE funding on June 22, 2022, marking a strategic financial move to bolster its operations. The company has completed 7 deals to date.

Tonix Pharmaceuticals primarily focuses on developing therapeutics across multiple therapeutic areas, including central nervous system disorders, immunology, infectious diseases, and rare diseases. Their core product offerings include two FDA-approved medications for acute migraine treatment in adults and a robust pipeline of product candidates, such as TNX-102 SL for fibromyalgia, TNX-1300 for cocaine intoxication, and TNX-1500 for organ transplant rejection. These treatments aim to address unmet medical needs, particularly for chronic conditions and pathologies with limited therapeutic options. The company's products are targeted toward healthcare providers, hospitals, and patients in the United States, as well as markets that include Europe and other regions, as their development and marketing strategies expand globally.

Tonix Pharmaceuticals generates revenue primarily through the sales of its FDA-approved products and potential future revenues from its pipeline candidates upon successful commercialization. In 2024, the company reported revenue of USD 10. 09 mn and an EBITDA of USD -133. 28 mn.

Transactions are structured through direct sales to healthcare providers and hospitals, with a focus on partnership agreements for product distribution. The company builds relationships with healthcare institutions and providers to facilitate the adoption of its therapies, ensuring alignment with clinical needs. Their revenue model emphasizes leveraging partnerships, particularly for their investigational products that may offer unique therapeutic benefits. While specific pricing details for individual products are not disclosed, the company’s strategy is built around comprehensive patient access programs and collaborations with healthcare networks to optimize market penetration.

Tonix Pharmaceuticals plans to expand its product pipeline and geographic reach, focusing on new therapeutics for underserved conditions. With the USD 30. 00 mn raised through PIPE funding in June 2022, the company intends to accelerate the development of its investigational products and enhance its market presence. Specific expansion plans include targeting markets in Europe and beyond, aligning with their development strategies to ensure broader patient access to their therapies.